Table 1. Clinical and pathological characteristics of the patient cohort in the original cohort.
| Plasma cohort | Urine cohort | ||||
| Low-Risk | High-Risk | Low-Risk | High-Risk | ||
| n | 33 | 37 | 17 | 16 | |
| Age | Median | 64 | 67 | 63 | 66 |
| (yrs) | Range | 48–74 | 57–81 | 52–72 | 57–81 |
| Follow-up | Median | 3.89 | 4.44 | 4.24 | 4.39 |
| (yrs) | Range | 1.16–6.02 | 1.65–7.01 | 3.65–5.05 | 2.12–5.10 |
| Prostate Weight | Median | 58 | 46 | 58 | 48 |
| (g) | Range | 28–86 | 20–118 | 34–86 | 20–64 |
| Gleason Grade (%) | 6 | 33 (100) | 0 (0) | 17 (100) | 0 (0) |
| 7 (3+4) | 0 (0) | 7 (19) | 0 (0) | 1 (6) | |
| 7 (4+3) | 0 (0) | 8 (22) | 0 (0) | 3 (19) | |
| 8 | 0 (0) | 3 (8) | 0 (0) | 1 (6) | |
| 9 (4+5) | 0 (0) | 16 (43) | 0 (0) | 8 (50) | |
| 9 (5+4) | 0 (0) | 3 (8) | 0 (0) | 3 (19) | |
| Tumour Volume | Median | 0.20 | 7.76 | 0.20 | 9.45 |
| (cc) | Range | 0.04–0.90 | 0.85–28.70 | 0.09–0.80 | 1.40–25.20 |
| pT stage (%) | pT2a | 12 (36) | 0 (0) | 6 (35) | 0 (0) |
| pT2b | 0 (0) | 2 (5) | 0 (0) | 1 (6) | |
| pT2c | 21 (64) | 6 (16) | 11 (65) | 3 (19) | |
| pT3a | 0 (0) | 13 (35) | 0 (0) | 5 (31) | |
| pT3b | 0 (0) | 16 (44) | 0 (0) | 7 (44) | |
| EPE (%) | Present | 0 (0) | 27 (73) | 0 (0) | 10 (63) |
| Absent | 33 (100) | 10 (27) | 17 (100) | 6 (37) | |
| SV Invasion (%) | Present | 0 (0) | 5 (14) | 0 (0) | 1 (6) |
| Absent | 33 (100) | 32 (86) | 17 (100) | 15 (94) | |
| PN Invasion (%) | Present | 7 (21) | 35 (95) | 2 (12) | 16 (100) |
| Absent | 26 (79) | 2 (5) | 15 (88) | 0 (0) | |
| LV Invasion (%) | Present | 0 (0) | 18 (49) | 0 (0) | 9 (56) |
| Absent | 33 (100) | 19 (51) | 17 (100) | 7 (44) | |
| Multifocal (%) | Yes | 25 (76) | 25 (68) | 12 (71) | 10 (63) |
| No | 8 (24) | 12 (32) | 5 (29) | 6 (37) | |
| Surgical Margins (%) | Positive | 1 (3) | 26 (70) | 1 (6) | 9 (56) |
| Negative | 32 (97) | 11 (30) | 16 (94) | 7 (44) | |
| Metastatic Disease (%) | Yes | 0 (0) | 5 (14) | 0 (0) | 2 (13) |
| No | 33 (100) | 32 (86) | 17 (100) | 14 (87) | |